Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00733525
Other study ID # 9802M00108
Secondary ID R01MH059304R01MH
Status Completed
Phase N/A
First received
Last updated
Start date September 2000
Est. completion date August 2005

Study information

Verified date October 2019
Source University of Minnesota
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will compare the medical and cost effectiveness of a stepped approach, including self-help and drug therapies, to the current best available care for bulimia nervosa.


Description:

The eating disorder bulimia nervosa (BN) is estimated to exist in 1 % to 2 % of women from the ages of 15 to 30, and bulimic behaviors occur in many more who do not develop the disorder. Characteristic symptoms include binge eating and self-induced vomiting. Research indicates that cognitive behavioral therapy (CBT), paired with use of the antidepressant fluoxetine, is the treatment of choice for BN. However, a survey of doctoral level psychologists dealing with eating disorders found that 78% of clinicians had no training in CBT for eating disorders, with 72% also untrained in the alternative, interpersonal therapy. Self-help manuals based on CBT have been developed as a treatment option for those without access to a clinician trained in CBT for eating disorders. Studies of these manuals suggest that self-guided therapy is as effective as CBT for some individuals. Additionally, although little research has examined cost effectiveness for treatment of eating disorders, a self-help approach may be more cost effective than CBT. This study will test whether self-help therapy, in the context of a stepped treatment plan involving check-ins with a clinician and possible drug treatment, can be an effective alternative, medically and economically, to traditional CBT.

Participants at four treatment sites will be screened for diagnosis, health, and presence of other conditions through assessments in standardized questionnaires, clinical interviews, and a blood test. Participants who pass the screening will be randomly assigned to one of two treatment sequences. In the first sequence, participants will be given twenty 50-minute sessions of individual CBT treatment over 18 weeks, focusing on altering eating behaviors. If participants do not have an adequate initial response to treatment by session six, they will be offered a trial of fluoxetine in addition to their continued CBT treatment. If they do not meet response criteria at the end of the 18 weeks of CBT treatment, they will again be given the option of taking or continuing to take fluoxetine until the termination of the study. The second sequence will begin with a specially designed self-help program aimed at teaching the same skills that will be taught in CBT sessions. Participants will have nine 30-minute checkup sessions with a therapist over 18 weeks. Participants who do not respond adequately to the treatment after 10 weeks will be given the option of taking fluoxetine. Participants without sufficient recovery at the end of 18 weeks will be given the option of undergoing the first treatment sequence.

Assessments of costs and health will be made at five points: the beginning of the study, and at the study visits on Week 10, Week 18, Week 36, and Week 62. Multiple assessments will be used to test health, including eating disorder symptoms, presence of other psychopathology and personality factors, social and interpersonal functioning, and quality of life. Eating disorder symptoms will be evaluated through clinical interview, questionnaires, and weight fluctuations. Treatment variables will also be assessed, with particular interest in the measure of patient knowledge of CBT techniques, to determine how much information from the self-help manual is used and absorbed. For the cost benefit analysis, assessments will include cost of health care visits, medications, treatments, and time lost due to illness. Data on cost will be collected at study visits, except for time lost, which will be measured through a questionnaire completed by a family member once at baseline and once after 18 weeks of treatment.


Recruitment information / eligibility

Status Completed
Enrollment 293
Est. completion date August 2005
Est. primary completion date April 2005
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Diagnosis of bulimia nervosa

Exclusion Criteria:

- Weight less than 85% of ideal

- Current substance abuse or dependence

- Pregnant

- Currently receiving psychotherapy

Study Design


Intervention

Behavioral:
Cognitive Behavioral Therapy
Therapy focusing on skills needed to alter eating patterns
Drug:
Fluoxetine
20 mg/day of fluoxetine, which can be incrementally increased to 80 mg/day
Behavioral:
Guided Self-Help
Manual designed to impart teachings of cognitive behavioral therapy

Locations

Country Name City State
United States University of North Dakota / Neuropsychiatric Research Institute Fargo North Dakota
United States University of Minnesota Minneapolis, MN Minneapolis Minnesota
United States Stanford University Palo Alto California
United States Cornell University; White Plains, NY White Plains New York

Sponsors (2)

Lead Sponsor Collaborator
University of Minnesota National Institute of Mental Health (NIMH)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Eating disorders examination Measured at baseline and Weeks 10, 18, 36, and 62
Secondary Records of health care, medications, and treatments Measured at baseline and Weeks 10, 18, 36, and 62
Secondary Height, weight, and body mass index Measured at baseline, Week 8, and Week 62
Secondary Battery of self-report questionnaires Measured at baseline and Weeks 10, 18, 36, and 62
Secondary Questionnaire on time lost to bulimia, completed by a family member Measured at baseline and after 18 weeks of treatment
See also
  Status Clinical Trial Phase
Recruiting NCT05656859 - Prevalence of Eating Disorders Among Patients in the Department of Health Promotion
Completed NCT04085861 - Mental Health in Dancers; an Intervention Study N/A
Recruiting NCT05651295 - A Precision Medicine Approach to Target Engagement for Emotion Regulation N/A
Enrolling by invitation NCT04174703 - Preparing for Eating Disorders Treatment Through Compassionate Letter-Writing N/A
Terminated NCT04278755 - Binge Eating & Birth Control Phase 2
Withdrawn NCT03050632 - Effects of Cognitive and Emotional Functioning on Treatment Outcomes N/A
Completed NCT02484794 - Augmenting Specialty Eating Disorder Clinical Treatment With a Smartphone Application N/A
Completed NCT02567890 - Swedish Body Project for Prevention of Eating Disorders N/A
Completed NCT02252822 - Improving Treatment Engagement for Adolescents With Bulimia Nervosa N/A
Completed NCT02021344 - Mental Health First Aid for College Students N/A
Completed NCT00601354 - Adding Guided Self-Help Group Therapy to the Alli Weight Loss Program in Treating Binge Eating Disorder N/A
Completed NCT00418977 - Comparing the Effectiveness of Two Therapies to Treat Signs of Anorexia Nervosa in Adolescents N/A
Completed NCT00304187 - Effectiveness of Antibiotic Treatment for Reducing Binge Eating and Improving Digestive Function in Bulimia Nervosa Phase 2
Active, not recruiting NCT04779216 - Effects of Romosozumab on Bone Density in Women With Anorexia Nervosa Phase 3
Completed NCT04433663 - Eating Disorders, Self Regulation and Mentalization N/A
Recruiting NCT05509257 - Naltrexone Neuroimaging in Teens With Eating Disorders Early Phase 1
Completed NCT04509531 - Building Resilience in Cyberbullying Victims N/A
Recruiting NCT05730348 - Mealtime Anxiety in Eating Disorders
Enrolling by invitation NCT05814653 - A Study to Evaluate Primary Care Treatment for Adolescent Eating Disorders N/A
Completed NCT04506216 - Eating Disorders in Type 1 Insulin-dependent Diabetes Patients N/A